Title: Clinical and genomic epidemiology of *mcr-9*-carrying carbapenem-resistant Enterobacterales isolates in Metropolitan Atlanta, 2012-2017

Authors: Ahmed Babiker^{1,2}, Chris Bower³⁻⁵, Joseph D. Lutgring⁶, Jessica Howard-Anderson¹, Uzma Ansari⁶, Gillian McAllister⁶, Michelle Adamczyk^{6,7}, Erin Breaker⁶, Sarah W. Satola^{1,2,3}, Jesse T. Jacob^{1,3}, Michael H. Woodworth^{1,3}

Affiliations:

1- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA

2- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA

3- Georgia Emerging Infections Program, Decatur, GA

4- Atlanta VA Medical Center, Decatur, GA

5- Foundation for Atlanta Veterans Education and Research, Decatur, GA

6- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

24

25 7- Goldbelt C6, LLC, Chesapeake, Virginia, USA

26

27 **Running title:** Genomic epidemiology of mcr-9

28

29 **Key words:** healthcare epidemiology, next generation sequencing, CRE, MDR, AMR

30

31 **Corresponding Author:** Michael H. Woodworth, Division of Infectious Diseases,

32 Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.

33 Email: michael.holmes.woodworth@emory.edu

34

35 **Alternative Corresponding author:** Ahmed Babiker, Division of Infectious Diseases,

36 Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.

37 Email: ahmed.babiker@emory.edu

Abstract (Word limit: 250, word count: 250)

Colistin is a last-resort antibiotic for multidrug-resistant gram-negative infections. Recently, the ninth allele of the mobile colistin resistance (*mcr*) gene family, designated *mcr-9*, was reported. However, its clinical and public health significance remains unclear. We queried genomes of carbapenem-resistant Enterobacterales (CRE) for *mcr-9* from a convenience sample of clinical isolates collected between 2012-2017 through the Georgia Emerging Infections Program, a population- and laboratory-based surveillance program. Isolates underwent phenotypic characterization and whole genome sequencing. Phenotypic characteristics, genomic features, and clinical outcomes of *mcr-9* positive and negative CRE cases were then compared. Among 235 sequenced CRE genomes, thirteen (6%) were found to harbor *mcr-9*, all of which were *Enterobacter cloacae* complex. The median MIC, rates of heteroresistance and inducible resistance to colistin were similar between *mcr-9* positive and negative isolates. However, rates of resistance were higher among *mcr-9* positive isolates across most antibiotic classes. All cases had significant healthcare exposures. The 90-day mortality was similarly high in both *mcr-9* positive (31%) and negative (7%) CRE cases. Nucleotide identity and phylogenetic analysis did not reveal geo-temporal clustering. *mcr-9* positive isolates had a significantly higher number of median [range] AMR genes (16 [4-22] vs. 6 [2-15]; $p < 0.001$) compared to *mcr-9* negative isolates. Pan genome tests confirmed a significant association of *mcr-9* detection with mobile genetic element and heavy metal resistance genes. Overall, the presence of *mcr-9* was not associated with significant changes in colistin resistance or clinical outcomes but continued genomic surveillance to monitor for emergence of AMR genes is warranted.

Introduction

With the rise of carbapenem-resistant organisms over the past few decades (1, 2), polymyxins (colistin or polymyxin B) remain last-resort antibiotics for multidrug-resistant gram-negative infections (3). While concerns regarding efficacy and nephrotoxicity (4) have relegated polymyxins to the second or third line of the antibiotic armamentarium (5), these agents remain listed as critically important antibiotics by the WHO and are widely used globally.

In 2015, a colistin-resistance gene localized on a plasmid was designated mobilized colistin resistance-1 (*mcr-1*) (6). The *mcr-1* gene encodes a transferase that adds a phosphoethanolamine residue to cell membrane lipid A, altering the binding site of colistin, and consequently leading to colistin resistance (6). Since its initial description in *Escherichia coli* (6), multiple *mcr* alleles (*mcr-2* to *mcr-10.1*) have been described (7). The *mcr-9* allele was reported in 2019 and is most similar to *mcr-3* among previously described *mcr* alleles (8). A recent search of publicly-available sequence databases revealed a wide global distribution of *mcr-9*-harboring isolates, across six continents and in at least 9 *Enterobacterales* species (7, 9). However, it is most commonly detected among *Enterobacter* species (9).

In the US, the initial wave of carbapenem-resistant Enterobacterales (CRE) was predominantly driven by proliferation of KPC-harboring *Klebsiella pneumoniae* (1, 10);

however, as demonstrated in recent reports, a second wave of CRE in the US seems to be driven by the rise of *Enterobacter* species (1, 11). Genomic analysis indicates this second wave is associated with a high degree of clonal diversity among isolates (12). With the increasing spread of carbapenem-resistant *Enterobacter*, the dissemination of *mcr-9* is highly probable. Despite its global distribution, the impact of *mcr-9* on colistin phenotypic susceptibility remain unclear. Moreover, its association with patient clinical outcomes or potential for outbreaks of public health concern is yet to be examined.

The Centers for Disease Control and Prevention (CDC)-funded Georgia Emerging Infections Program (GA EIP) performs active, population- and laboratory- based surveillance for CRE isolated from sterile sites or urine in metropolitan Atlanta, GA (population ~4 million). We aimed to estimate the frequency of *mcr-9* among CRE cases within the GA EIP catchment area and to compare clinical outcomes and microbiological, genomic, and clinical characteristics of *mcr-9* positive and *mcr-9* negative cases.

Results

The mcr-9 allele was infrequently detected among GA EIP isolates between 2012-2017

Between 2012-2017, the GA EIP identified 1,507 incident CRE cases, 716 (47.5%) were *K. pneumoniae*; 415 (27.5%), *Escherichia coli*; 270 (17.9%), *Enterobacter cloacae* complex; 72 (4.8%), *Klebsiella aerogenes* (formerly *Enterobacter*); and 34 (2.3%)

Klebsiella oxytoca cases. The overall crude annual CRE incidence across GA EIP increased from 4.6 to 9.6 per 100,000 population from 2012 to 2017. Carbapenem-resistant *E. cloacae* complex incidence, in particular, increased from 0.37 to 2.3 per 100,000 population during the study period. This increase coincided with revision of the CDC case surveillance definition for CRE (13). **(Figure 1 A/B, Supplementary Table 1, Supplementary Figure 1).**

A convenience sample of 384 isolates which met the GA EIP CRE case definition was sent to the CDC for further characterization. Of the 384, 235 (61%) underwent whole genome sequencing (WGS). Among 235 sequenced CRE isolates, thirteen (6%) were found to harbor *mcr-9*, all of which were *E. cloacae* complex. All remaining sequenced *mcr-9* negative *E. cloacae* complex (n=14) were included as a comparative group, yielding a total number of 27 *E. cloacae* complex isolates.

Microbiology Characteristics

Following collection, isolates underwent reference antimicrobial susceptibility testing by broth microdilution (BMD) at CDC. Of the *E. cloacae* complex isolates that underwent WGS from 2012-2017, twenty-two isolates (81.7%, 22/27) were confirmed to be carbapenem-resistant. Carbapenem resistance was similar among *mcr-9* positive and negative cases (84.6% (11/13) vs. 78.6% (11/14); $p=1.00$). Fluoroquinolone resistance was significantly higher among *mcr-9* positive isolates compared to *mcr-9* negative isolates (100% (13/13) vs. 57.1% (8/14); $p=0.03$). This contributed to a higher proportion

of isolates being classified as difficult-to-treat resistance (DTR) (14). Overall, 48.1% (13/27) were classified as harboring DTR (14, 15). with *mcr-9* isolates having higher-rates of DTR (61.5% (8/13) vs. 35.7% (5/14) $p=0.34$). Similarly, rates of aminoglycoside, tetracycline, and trimethoprim-sulfamethoxazole resistance were higher among *mcr-9* positive isolates compared to *mcr-9* negative isolates (**Supplementary Table 2**).

The median [range of concentrations tested] colistin MIC for all *E. cloacae* complex isolates was 0.5 $\mu\text{g/mL}$ [≤ 0.25 ->8.0]. Proportions of resistance, heteroresistance and inducible resistance were 11.1% (3/27), 48.1% (13/27) and 14.8% (4/27), respectively. There was no significant difference in colistin MIC, heteroresistance or inducible resistance between *mcr-9* positive and negative isolates (**Table 1**). Of the three *E. cloacae* complex isolates which were colistin-resistant by BMD, none were *mcr-9* positive, although one was positive for *mcr-10.1*.

Clinical characteristics of mcr-9 positive and negative CRE cases.

E. cloacae complex isolates were commonly isolated from urine (88.9%, 24/27), followed by blood (7.4%, 2/27) and peritoneal fluid (3.7%, 1/27). All cases had significant healthcare exposures, with 14 cases (51.9%) long term care facility onset, 10 (37.0%) healthcare-associated community onset, and 3 (11.1%) hospital onset. Ten patients (37.0%) were hospitalized at time of culture or within 29 days of CRE culture. Among the 10 hospitalized patients, 3 (30.0%) patients were admitted to the ICU within seven days of culture and one patient died during the period of hospitalization (10.0%).

Among hospitalized patients with available follow up data (n=7), 42.8% (3/7) were readmitted within 30 days. Overall unadjusted all-cause 90-day mortality was 18.5% (5/27). No clinical characteristics and outcomes were significantly different, and most were numerically similar among *mcr-9* positive and negative cases. 90-day mortality was higher among *mcr-9* positive cases (30.7% (4/13) vs. 7.1% (1/14)) compared to *mcr-9* negative cases but this was not statistically significant ($p=0.28$).

Genomic Analysis

To expand the analytic genome set, a comparator cohort of nine publicly-available clinical and environmental carbapenem-resistant *E. cloacae* complex (three *mcr-9* positive, six *mcr-9* negative) genomes downloaded from National Center for Biotechnology Information (NCBI). Review of associated metadata revealed isolates to have been collected between January 2012 and December 2016 at the National Institutes of Health (NIH) clinical center (Bethesda, MD) (PRJNA430442) (16). These genomes were combined with the 27 GA EIP isolates, resulting in 36 isolate draft genomes included in further comparative genomic analyses.

The 13 *mcr-9* positive *E. cloacae* complex isolates were obtained from 10 distinct GA EIP facilities across the study period (2012-2017). Average nucleotide identity pairwise comparisons revealed three distinct clusters (**Figure 2**). This clustering did appear to be related to geographical location or year of isolation. NIH isolates clustered with GA EIP isolates, and GA EIP isolates did not cluster by facility or year (**Supplementary Figure**

2). Their distribution throughout the genome phylogeny suggested that the *mcr-9* positive isolates were largely genetically distinct from one another.

Median [range] AMR gene content (excluding *mcr-9*) was significantly higher among *mcr-9* positive isolates compared to *mcr-9* negative isolates (16 [4-22] vs. 6 [2-15]; $p < 0.001$) (**Figure 3**). Among the three isolates with elevated colistin MICs, no point mutations in *pmrA/pmrB*, a two-component system regulator of lipopolysaccharide (the target site of colistin) modifications, were detected. Pan-genome-wide association tests revealed a significant association of *mcr-9* detection with the detection of mobile genetic element (MGE)-associated genes such as *repB*, *parM*, *hns2*; heavy metal resistance (HMR) genes such as *arsC2*, *arsB2*, *fieF2*, *pcoE2* and *merA*; and virulence genes such as *hipA* (**Table 2, Supplementary Table 2, Supplementary Figure 3**). Taken together, these comparative genomic analyses across two sites with *mcr-9* positive *E. cloacae* complex isolate draft genomes confirmed the colocalization of *mcr-9* with plasmid-mobilized heavy metal resistance genes but did not provide evidence of a high-identity outbreak cluster in space or time.

Discussion

Among 235 CRE isolates collected through a comprehensive, population-based surveillance program targeting the most common CRE species, we found a low prevalence of *mcr-9*, all of which were detected in *Enterobacter cloacae* isolates. Our phylogenetic analyses revealed a genetically diverse *mcr-9* positive CRE population,

suggesting sporadic carriage rather than clonal spread. Using multi-modal phenotypic testing, we were unable to detect impacts of *mcr-9* on colistin susceptibility, however genomic analysis revealed an association with increased AMR, HMR and virulence genes. In addition, our *mcr-9*-containing CRE isolates were exclusively acquired in healthcare settings, with a trend towards increased mortality. Since their initial description, recognition of *mcr* genes associated with colistin resistance has spread rapidly across the globe (7). Our study of *mcr-9*-harboring CRE cases provides unique insights into the phenotypic and genomic implications of *mcr-9*, and is one of the first to examine clinical outcomes.

Whether *mcr-9* confers colistin resistance has been debated (17). The first isolate identified to harbor *mcr-9* was also susceptible to colistin but the allele was found to confer resistance to colistin when cloned into a colistin-susceptible *E. coli* and expressed under the control of an IPTG-induced promoter. However, this was only at 1, 2, and 2.5 mg/L, but not at 5 mg/L of colistin (8). Kieffer *et al.* later reported that *mcr-9* expression was inducible in the presence of colistin when located upstream of the two-component sensor kinase system *qseBC* (17). This two-component signaling network allows bacteria to sense and respond to their changing environments. In particular, the *qseC* and *qseB* genes encode a histidine kinase sensor (*qseC*) and its cognate partner (*qseB*). The *qseBC* system has been shown to interact with *pmrA/pmrB*, to induce resistance to the colistin(18). However, a study of *mcr-9*-containing isolates from retail meat conducted by the National Antimicrobial Resistance Monitoring System (NARMS), found all 105 isolates (99 *S. enterica* and 6 *E. coli*) tested to be susceptible to colistin,

including 10 isolates with *qseBC* (19), indicating that the previously demonstrated impact of *qseBC* on *mcr-9* expression and colistin resistance may be dependent on strain backgrounds, as originally demonstrated in *E. coli* (17). Among clinical CRE isolates, we found the presence of *mcr-9* was not associated with frank or inducible colistin resistance. Furthermore, our study is the first to examine the association of *mcr-9* with heteroresistance. Heteroresistance is a largely unrecognized form of antibiotic resistance where only a subset of cells within a bacterial population are resistant to a given drug (20). These resistant cells can be selected for in the presence of the antibiotic and cause colistin treatment failures *in-vivo* (21). In a multisite surveillance study of colistin heteroresistance among CRE, *Enterobacter spp.* and in particular *E. cloacae*, displayed the highest proportion of colistin heteroresistance (22). However, here we found no association between *mcr-9* and colistin heteroresistance.

Carbapenem-resistant gram-negatives are a public health threat broadly prioritized by public health organizations (23). Given the limited therapeutic options, morbidity and mortality rates are increased disproportionately when compared to infections caused by susceptible bacteria. We observed high 90-day mortality rates, but these were similar to reported CRE mortality rates at other US academic centers (1). However, there was a non-significant trend for higher mortality among *mcr-9* positive isolates. This association should be further evaluated in larger studies, with adjustment for potentially-confounding variables associated with mortality such as severity of illness, age and comorbidities as our small size may underestimate differences in mortality (1). This finding may be related to the increase in phenotypic resistance and AMR gene content associated with

mcr-9. A similar finding was previously reported describing 1,035 *mcr-9*-containing isolates in which 97% (1003/1035) were classified as MDR (7). This increased AMR gene content, renders isolates not only carbapenem-resistant, but also with DTR, further limiting therapeutic options (14). DTR is a clinically relevant and functional classification of resistance which signifies *in vitro* resistance to all high-efficacy, low-toxicity (or first-line) agents and is associated with worse clinical outcomes when compared to carbapenem-resistant phenotypes (14). Moreover, genome-wide association studies, revealed a difference in key virulence genes such *hipA*, a eukaryote-like serine threonine kinase that inhibits cell growth and induces bacterial persistence (24).

We found the presence of *mcr-9* to be associated with HMR genes such *arsA*, *merA*, conferring arsenic and mercury resistance, respectively. There has been increasing evidence for the co-selection of AMR and HMR genes through either co-resistance or cross-resistance (25). Co-resistance occurs when AMR and HMR genes are carried on the same mobile genetic element. IncH12 plasmids, which frequently harbor HMR genes (8), have been found to be the predominant replicon type carrying *mcr-9* and frequently demonstrated in our isolates. Hospital wastewater is an increasingly recognized reservoir for resistant gram-negative organisms that cause healthcare-associated infections (26) and HMR genes may allow for continued persistence in the environment (27). While the community setting is starting to represent an increased source of multidrug-resistant infections (28), the healthcare setting still represents a major risk for MDR acquisition, as was seen among our cohort.

268

269 Our study combines detailed epidemiological, clinical, phenotypic, and genomic data to
 270 examine the significance of *mcr-9* but has some limitations. Firstly, we could not do a
 271 full interrogation of *mcr-9*-containing plasmids, due to limitations of short read
 272 sequencing. However, prior studies have significantly characterized the genomic
 273 background of *mcr-9*-containing plasmids (9). Second, our study did not include
 274 *Salmonella* species which are a major reservoir for *mcr-9* or other *Enterobacterales*
 275 species such as *Citrobacter* (7) , and our findings may not be generalizable to these
 276 species. However, our dataset of 235 includes the most common and significant clinical
 277 CRE species (1, 23) and is one of few studies carried out on clinical human isolates
 278 (19). Third, while we assessed for presence of the *pmrA/pmrB* regulatory system (29),
 279 we did not include assessment of the two-component system *qseBC* (8) or testing
 280 conditions (such as the use of cation-adjusted Mueller-Hinton broth) (30) which have
 281 been shown to influence *mcr-9* expression and the colistin MIC results, respectively.
 282 Fourth, while our overall cohort is from a population-based surveillance program, the
 283 collected and sequenced isolates represent a convenience sample which may limit
 284 generalizability and our sample size was not powered to detect clinical outcomes.

285

286 In conclusion, *mcr-9* may not have actionable public health implications as other *mcr*
 287 alleles, most of which consistently display colistin resistance. However, given the
 288 increased AMR and HMR gene content, continued genomic surveillance of multidrug-
 289 resistant organisms to monitor for the emergence of AMR genes such as *mcr-9* is

prudent. Especially as changes in the up or downstream genetic context or the accumulation of mutations may impact its ability to confer colistin resistance.

Methods

CRE cases were identified by routine queries on automated testing instruments in the clinical labs that serve residents of the GA EIP catchment area. Clinical characteristics were obtained through medical record review, all-cause mortality data was obtained through the Georgia Vital Statistics records, and hospital readmission data was obtained through the Department of Public Health's hospital discharge datasets. Georgia EIP surveillance activities are reviewed and approved by the Emory University Institutional Review Board.

From 2012-2015, a CRE case was defined as an isolate of *E. coli*, *E. cloacae* complex, *K. (formally Enterobacter) aerogenes*, *K. pneumoniae*, or *K. oxytoca* collected from a normally sterile body site (e.g., bloodstream) or urine that tested non-susceptible to ≥ 1 carbapenem (imipenem, meropenem, or doripenem) and resistant to all 3rd generation cephalosporins tested (ceftriaxone, ceftazidime, and cefotaxime) by testing performed at the local collection microbiology laboratory. Beginning in 2016, the phenotypic case definition was changed to resistance to ≥ 1 carbapenem (now including ertapenem) with no cephalosporin parameter. Antibiotic susceptibility interpretations were determined using the current Clinical and Laboratory Standards Institute breakpoints (31). Fluoroquinolone resistance was defined as non-susceptibility

(intermediate or resistant) to ≥ 1 fluoroquinolone. DTR was defined as intermediate or resistant to all reported agents in carbapenem, β -lactam, and fluoroquinolone categories (14, 15).

An incident CRE case was defined as the first CRE isolate from a patient during a 30-day period that met the surveillance definition. All incident CRE cases underwent medical record review using a standardized abstraction form. Both inpatient and outpatient medical records were reviewed for patient demographics, underlying clinical comorbidities, location of culture collection, specimen source, associated infectious syndromes, relevant health care exposures and patient outcomes. 90-day mortality was determined based by matching to vital records.

A convenience sample of CRE isolates are collected annually and submitted to the CDC for further characterization. Isolates that are collected and matched to an incident case with a completed case report form are eligible for shipment. All isolates undergo repeat reference BMD at the CDC followed by whole genome sequencing using an Illumina MiSeq benchtop sequencer.

All *mcr-9* positive and a comparative control group of *mcr-9* negative *E. cloacae* complex isolates underwent additional population analysis profiling and inducible resistance testing at the Emory Investigational Clinical Microbiology Core as previously described (20). Briefly, all isolates were tested via the population analysis profile (PAP) method. This consists of plating overnight cultures of each isolate onto solid Muller-

Hinton (MH) agar with or without colistin concentrations of 0.5, 1, 2, 4, 16, 32, and 100 µg/ml. Surviving colonies were enumerated and used to detect colistin-resistant subpopulations characteristic of heteroresistance (20). Inducible resistance testing was performed as previously described (32). Briefly, a single colony of each clinical isolate was grown in Muller-Hinton (MH) broth overnight at 37°C, and cultures were diluted 1:100 in MH broth containing serially increasing concentrations of colistin, starting at the one-half MIC value of the respective isolate, and doubling every 24 hours until bacterial growth was completely inhibited (with no bacteria growth after spreading 100 µL of the culture on MH agar plates supplemented with corresponding concentration of colistin). The concentration of colistin at which bacterial growth was completely inhibited was recorded as the final colistin concentration.

Bioinformatic Methods

Fastq files of *Enterobacter cloacae* complex isolates of interest were downloaded from the Sequence Read Archive (SRA) repository maintained by the National Center for Biotechnology Information (NCBI) using the fasterq-dump tool from the SRA Toolkit V. 2.5.7 (<http://ncbi.github.io/sra-tools/>). Illumina reads were quality filtered using Trimmomatic (33) and assembled *de novo* using SPAdes v3.13 (34). Pairwise comparisons of average nucleotide identity on the assembled genomes were performed with the Mashmap method using fastANI v1.32 (35). Gene sequences were predicted with Prodigal v2.6.3 (36) and annotated with Prokka v1.14.6 (37). Antimicrobial resistance and virulence gene content was assessed using AMRFinder Plus (38).

Presence of plasmids and point mutations in housekeeping genes associated with colistin resistance were assessed using the ResFinder and PlasmidFinder web interface with default settings and the *E. coli* database (39, 40). AMR gene presence/absence heatmaps were created using the package pheamap on R version 4.0.2 (Vienna, Austria) and the RStudio interface version 1.3.1073 (Boston, MA, USA). Core genes were defined using Roary v3.13 (41). A phylogenetic tree based on a core gene alignment containing 1942 genes was generated using IQtree v2.0.3 (42). A maximum likelihood tree was generated by running 1,000 bootstrap replicates under the generalized time-reversible model of evolution. The tree was visualized and annotated using Interactive Tree of Life (iTOL) v4 (43). Pan-genome wide comparison of core genomes of *mcr-9* positive to *mcr-9* negative genomes was completed using scoary (44).

Statistical analysis

Annual incidence rates for CRE cases were calculated using the annual US census estimates of the surveillance area population as the denominator. Descriptive analyses were performed to summarize specimen information, health care exposures, outcomes, and microbiological results of incident cases; χ^2 and Wilcoxon rank sum tests were used to compare groups when applicable. Gene differences were assessed by a *p*-value adjusted with Bonferroni's method for multiple comparisons correction. Statistical analysis was performed using R version 4.0.2 (Vienna, Austria) and the RStudio

interface version 1.3.1073 (Boston, MA, USA). A 2-sided P value of <.05 was considered statistically significant.

Funding

EIP Surveillance of the Multi-site Gram-Negative Surveillance Initiative (MuGSI) was funded through the Centers for Disease Control and Prevention's Emerging Infections Program [U50CK000485].

Acknowledgments

We would like to thank the EIP and MuGSI staff and the CDC laboratory staff for their dedication and work to collect, validate, clean, and maintain the data used in this analysis. We would like to thank Alison Laufer Halpin for supervising the sequencing efforts of these isolates.

399 **Table 1: Carbapenem-resistant *E. cloacae* complex clinical and microbiological**
 400 **characteristics**
 401

	All (N=27) n (%)	<i>mcr-9</i> positive (N=13) n (%)	<i>mcr-9</i> negative * (N=14) n (%)	<i>p</i> value
Culture Source				0.33
Urine	24 (88.9)	12 (92.3)	12 (85.7)	
Blood	2 (7.4)	1 (7.7)	1 (7.1)	
Peritoneal Fluid	1 (3.7)	0 (0.0)	1 (7.1)	
Year				0.62
2012	1 (3.7)	1 (7.7)	0 (0.0)	
2013	8 (29.6)	2 (15.4)	6 (42.9)	
2014	2 (7.4)	1 (7.7)	1 (7.1)	
2015	3 (11.1)	3 (23.1)	0 (0.0)	
2016	9 (33.3)	4 (30.8)	5 (35.7)	
2017	4 (14.9)	2 (15.4)	2 (14.3)	
Infection Onset				0.71
Hospital Onset	3 (11.1)	2 (15.4)	1 (7.1)	
Healthcare Associated-	10 (37.0)	4 (30.8)	6 (42.9)	
Community Onset				
Long Term Care Facility Onset	14 (51.9)	7 (53.8)	7 (50.0)	
Microbiology Characteristics				

Colistin MIC (median[range])**	0.5 [<0.25 - >0.8]	0.5 [<0.25 -1.00]	0.5 [<0.25 ->8.0]	0.11
Resistant	3 (11.1)	0	3 (21.4)	0.25
Heteroresistant	13 (48.1)	5 (38.5)	8 (57.1)	0.56
Inducible resistance	4 (14.8)	2 (15.4)	2 (14.3)	1.00
Difficult-to-Treat Resistance	13 (48.1)	8 (61.5)	5 (35.7)	0.34
Outcomes				
Hospitalization within 29 days after culture	10 (37.0)	5 (38.5)	5 (35.7)	0.86
ICU admission ***^	4 (40.0)	2 (40.0)	2 (40.0)	1.00
In-hospital mortality ^	1 (10.0)	1 (20.0)	0 (0.0)	0.59
90-day Mortality	5 (18.5)	4 (30.8)	1 (7.1)	0.28

402

403 *1 *mcr-10* positive isolate

404 ** MIC units : µg/mL

405 *** Any ICU admission 7 days prior or 6 days after specimen collection

406 ^ among 10 hospitalized patients, 5 in each group (*mcr-9* positive and negative)

407

Table 2. Highest ranking genes for association with *mcr-9* presence

Gene*	Comment	Odds Ratio	Bonferroni adjusted <i>p</i> - value
<i>smc</i>	Chromosome partition protein Smc	∞	1.60E-06
<i>dcm2</i>	DNA-cytosine methyltransferase	∞	1.60E-06
<i>pcoE2</i>	putative copper-binding protein PcoE	∞	2.88E-05
<i>hns2</i>	DNA-binding protein H-NS, plasmid	∞	3.36E-05
group_10390	Tn3 family transposase ISEc63	∞	3.36E-05
<i>hipA</i>	Serine/threonine-protein kinase toxin HipA	∞	3.36E-05
<i>rcnR2</i>	Transcriptional repressor RcnR	∞	0.00030219
<i>hha2</i>	Hemolysin expression-modulating protein Hha	∞	0.00036934
<i>uvrD2</i>	DNA helicase II	∞	0.00036934
parM	Plasmid segregation protein	∞	0.00036934
<i>higB-1</i>	Toxin HigB-1	∞	0.00036934
group_1846	Tn3 family transposase ISEc63	∞	0.00036934
<i>dam2</i>	DNA adenine methylase	∞	0.00036934
<i>repB</i>	RepFIB replication protein A	∞	0.00036934
<i>traC</i>	Protein TraC	∞	0.00036934
group_7173	Stable plasmid inheritance protein	∞	0.00036934
<i>yjcD</i>	Putative ATP-dependent DNA helicase YjcD	304	0.00054522
<i>umuD2</i>	Protein UmuD	∞	0.00283164

<i>dsbC_2</i>	Thiol:disulfide interchange protein DsbC	∞	0.00283164
<i>virB</i>	Virulence regulon transcriptional activator VirB	∞	0.00283164
<i>umuC_3</i>	Protein UmuC	∞	0.00283164
group_7174	IS110 family transposase ISEsa2	142.5	0.00540586
<i>merA</i>	Mercuric reductase	∞	0.01698985
<i>fieF_2</i>	Ferrous-iron efflux pump FieF	90.7	0.03283809
<i>arsB_2</i>	Arsenical pump membrane protein	67.5	0.04368339
group_7063	ISNCY family transposase ISEsa1	67.5	0.04368339
group_8953	ISNCY family transposase ISBcen27	67.5	0.04368339
<i>arsH</i>	NADPH-dependent FMN reductase ArsH	67.5	0.04368339
<i>arsC2</i>	Arsenate reductase	67.5	0.04368339

410

411 hypothetical proteins not included

412

413

414

415

416

Figure 1.

Figure Legend 1. Carbapenem-resistant Enterobacteriales (CRE) count (A) and crude annual incidence per 100,000 population (B) by species across from the Georgia Emerging Infections program from 2012 to 2017. Beginning in 2016, the phenotypic CRE case definition was changed to resistance to ≥ 1 carbapenem (now including ertapenem) with no cephalosporin parameter.

Figure 2

Figure Legend 2: Phylogeny (A) and average nucleotide identity heatmap (B) of *mcr-9* positive (n=13) and *mcr-9* negative (n=14) *E. cloacae* complex genomes from Georgia Emerging Infection program in addition to 9 available *E. cloacae* complex genomes (three *mcr-9* positive, six *mcr-9* negative) from the National Institutes of Health. A phylogenetic tree based on a core gene alignment containing 1,904 genes defined using Roary v3.13.0. was generated using IQtree v2.0.3. A maximum likelihood tree was generated by running 1,000 bootstrap replicates under the generalized time-reversible model of evolution. The tree was visualized and annotated using Interactive Tree of Life (iTOL) v4. Pairwise comparisons of average nucleotide identity on the assembled genomes were performed with the Mashmap method using fastANI v1.32.

454 Abbreviations: GA EIP: Georgia Emerging Infections Program, NIH: National Institutes
455 of Health,
456

Figure 3

Figure 3 Legend: Antimicrobial resistance gene heatmap of *mcr-9* positive (n=13) and *mcr-9* negative (n=14) *E. cloacae* complex genomes from Georgia Emerging Infections program in addition to 9 available *E. cloacae* complex genomes (three *mcr-9* positive, six *mcr-9* negative) from the National Institutes of Health. Genomes were annotated using Prodigal v2.6.3 and antimicrobial resistance gene content was assessed using

464 AMRFinder Antimicrobial resistance gene presence/absence heatmaps were
465 created using the package pheatmap on R version 4.0.2 (Vienna, Austria) and the
466 RStudio interface version 1.3.1073 (Boston, MA, USA).

References

1. Babiker A, Clarke LG, Saul M, Gealey JA, Clancy CJ, Nguyen MH, Shields RK. 2020. Changing epidemiology and decreased mortality associated with Carbapenem-resistant Gram-negative bacteria from 2000 - 2017. Clin Infect Dis doi:10.1093/cid/ciaa1464.
2. Babiker A, Evans DR, Griffith MP, McElheny CL, Hassan M, Clarke LG, Mettus RT, Harrison LH, Doi Y, Shields RK, Van Tyne D. 2020. Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible *Citrobacter* spp. at a Tertiary Health Care Center over 2 Decades. Journal of Clinical Microbiology 58:e00275-20.
3. World Health Organization. 2019. Critically important antimicrobials for human medicine, 6th revision
. www.who.int/foodsafety/publications/antimicrobials-sixth/en/. Accessed 7th May 2021.
4. Eljaaly K, Bidell MR, Gandhi RG, Alshehri S, Enani MA, Al-Jedai A, Lee TC. 2021. Colistin Nephrotoxicity: Meta-analysis of Randomized Controlled Trials. Open Forum Infectious Diseases doi:10.1093/ofid/ofab026.
5. Strich JR, Ricotta E, Warner S, Lai YL, Demirkale CY, Hohmann SF, Rhee C, Klompas M, Palmore T, Powers JH, Dekker JP, Adjemian J, Matsouaka R, Woods CW, Danner RL, Kadri SS. 2021. Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals. Clin Infect Dis 72:611-621.
6. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism *mcr-1* in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16:161-8.

7. Ling Z, Yin W, Shen Z, Wang Y, Shen J, Walsh TR. 2020. Epidemiology of mobile colistin resistance genes *mcr-1* to *mcr-9*. Journal of Antimicrobial Chemotherapy 75:3087-3095.
8. Carroll LM, Gaballa A, Guldumann C, Sullivan G, Henderson LO, Wiedmann M. 2019. Identification of Novel Mobilized Colistin Resistance Gene *mcr-9* in a Multidrug-Resistant, Colistin-Susceptible *Salmonella enterica* Serotype Typhimurium Isolate. mBio 10:e00853-19.
9. Li Y, Dai X, Zeng J, Gao Y, Zhang Z, Zhang L. 2020. Characterization of the global distribution and diversified plasmid reservoirs of the colistin resistance gene *mcr-9*. Scientific Reports 10:8113.
10. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. Lancet Infect Dis 13:785-96.
11. Wilson BM, El Chakhtoura NG, Patel S, Saade E, Donskey CJ, Bonomo RA, Perez F. 2017. Carbapenem-Resistant *Enterobacter cloacae* in Patients from the US Veterans Health Administration, 2006-2015. Emerg Infect Dis 23:878-880.
12. Annavajhala MK, Gomez-Simmonds A, Uhlemann AC. 2019. Multidrug-Resistant *Enterobacter cloacae* Complex Emerging as a Global, Diversifying Threat. Front Microbiol 10:44.
13. Chea N, Bulens SN, Kongphet-Tran T, Lynfield R, Shaw KM, Vagnone PS, Kainer MA, Muleta DB, Wilson L, Vaeth E, Dumyati G, Concannon C, Phipps EC, Culbreath K, Janelle SJ, Bamberg WM, Guh AY, Limbago B, Kallen AJ. 2015. Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae. Emerging infectious diseases 21:1611-1616.

14. Kadri SS, Lai YL, Ricotta EE, Strich JR, Babiker A, Rhee C, Klompas M, Dekker JP, Powers JH, III, Danner RL, Adjemian J, Initiative NAROR. 2019. External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals. Open Forum Infectious Diseases 6.
15. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH, 3rd, Suffredini AF, Hooper DC, Fridkin S, Danner RL. 2018. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis 67:1803-1814.
16. Weingarten RA, Johnson RC, Conlan S, Ramsburg AM, Dekker JP, Lau AF, Khil P, Odom RT, Deming C, Park M, Thomas PJ, Henderson DK, Palmore TN, Segre JA, Frank KM. 2018. Genomic Analysis of Hospital Plumbing Reveals Diverse Reservoir of Bacterial Plasmids Conferring Carbapenem Resistance. mBio 9.
17. Kieffer N, Royer G, Decousser J-W, Bourrel A-S, Palmieri M, Ortiz De La Rosa J-M, Jacquier H, Denamur E, Nordmann P, Poirel L. 2019. *mcr-9* an Inducible Gene Encoding an Acquired Phosphoethanolamine Transferase in *Escherichia coli*, and Its Origin. Antimicrobial Agents and Chemotherapy 63:e00965-19.
18. Breland EJ, Zhang EW, Bermudez T, Martinez CR, 3rd, Hadjifrangiskou M. 2017. The Histidine Residue of QseC Is Required for Canonical Signaling between QseB and PmrB in Uropathogenic *Escherichia coli*. J Bacteriol 199.
19. Tyson GH, Li C, Hsu C-H, Ayers S, Borenstein S, Mukherjee S, Tran T-T, McDermott PF, Zhao S. 2020. The *mcr-9* Gene of *Salmonella* and *Escherichia coli* is Not Associated with Colistin Resistance in the United States. Antimicrobial Agents and Chemotherapy 64:e00573-20.

20. Nicoloff H, Hjort K, Levin BR, Andersson DI. 2019. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification. *Nat Microbiol* 4:504-514.
21. Band VI, Satola SW, Burd EM, Farley MM, Jacob JT, Weiss DS, Hunstad DA, Hultgren SJ. 2018. Carbapenem-Resistant *Klebsiella pneumoniae* Exhibiting Clinically Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of Infection. *mBio* 9:e02448-17.
22. Band VI, Satola SW, Smith RD, Hufnagel DA, Bower C, Conley AB, Rishishwar L, Dale SE, Hardy DJ, Vargas RL, Dumyati G, Kainer MA, Phipps EC, Pierce R, Wilson LE, Sorensen M, Nilsson E, Jordan IK, Burd EM, Farley MM, Jacob JT, Ernst RK, Weiss DS. 2021. Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant Enterobacterales in the United States. *mBio* 12:e02881-20.
23. Centers for Disease Control. 2019. Antibiotic resistance threats in the United States, 2019.
24. Germain E, Castro-Roa D, Zenkin N, Gerdes K. 2013. Molecular mechanism of bacterial persistence by *HipA*. *Mol Cell* 52:248-54.
25. Nguyen CC, Hugie CN, Kile ML, Navab-Daneshmand T. 2019. Association between heavy metals and antibiotic-resistant human pathogens in environmental reservoirs: A review. *Frontiers of Environmental Science & Engineering* 13:46.
26. Kizny Gordon AE, Mathers AJ, Cheong EYL, Gottlieb T, Kotay S, Walker AS, Peto TEA, Crook DW, Stoesser N. 2017. The Hospital Water Environment as a Reservoir for Carbapenem-Resistant Organisms Causing Hospital-Acquired Infections—A Systematic Review of the Literature. *Clinical Infectious Diseases* 64:1435-1444.
27. Kamathewatta K, Bushell R, Rafa F, Browning G, Billman-Jacobe H, Marenda M. 2020. Colonization of a hand washing sink in a veterinary hospital by an *Enterobacter*

hormaechei strain carrying multiple resistances to high importance antimicrobials.

Antimicrobial Resistance & Infection Control 9:163.

28. Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, McCarthy N, Paul P, McDonald LC, Kallen A, Fiore A, Craig M, Baggs J. 2020. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. *N Engl J Med* 382:1309-1319.
29. Chen HD, Groisman EA. 2013. The biology of the PmrA/PmrB two-component system: the major regulator of lipopolysaccharide modifications. *Annu Rev Microbiol* 67:83-112.
30. Gwozdinski K, Azarderakhsh S, Imirzalioglu C, Falgenhauer L, Chakraborty T. 2018. An Improved Medium for Colistin Susceptibility Testing. *Journal of Clinical Microbiology* 56:e01950-17.
31. Clinical and Laboratory Standards Institute. 2021. Performance standards for antimicrobial susceptibility testing, 31st informational supplement.
32. Luo Q, Niu T, Wang Y, Yin J, Wan F, Yao M, Lu H, Xiao Y, Li L. 2019. In vitro reduction of colistin susceptibility and comparative genomics reveals multiple differences between MCR-positive and MCR-negative colistin-resistant *Escherichia coli*. *Infection and drug resistance* 12:1665-1674.
33. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30:2114-20.
34. Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. 2020. Using SPAdes De Novo Assembler. *Current Protocols in Bioinformatics* 70:e102.
35. Jain C, Rodriguez-R LM, Phillippy AM, Konstantinidis KT, Aluru S. 2018. High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. *Nature Communications* 9:5114.

36. Hyatt D, Chen GL, Locascio PF, Land ML, Larimer FW, Hauser LJ. 2010. Prodigal: prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics* 11:119.
37. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068-9.
38. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH, Hoffmann M, Pettengill JB, Prasad AB, Tillman GE, Tyson GH, Klimke W. 2021. AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. *Sci Rep* 11:12728.
39. Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. 2017. PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. *J Antimicrob Chemother* 72:2764-2768.
40. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrobial agents and chemotherapy* 58:3895-3903.
41. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, Fookes M, Falush D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics (Oxford, England)* 31:3691-3693.
42. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermini LS. 2017. ModelFinder: fast model selection for accurate phylogenetic estimates. *Nature Methods* 14:587-589.
43. Letunic I, Bork P. 2021. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation. *Nucleic Acids Research* doi:10.1093/nar/gkab301.

- 616 44. Brynildsrud O, Bohlin J, Scheffer L, Eldholm V. 2016. Rapid scoring of genes in
617 microbial pan-genome-wide association studies with Scoary. *Genome Biol* 17:238.
618

619 **Supplementary Material**

620 **Supplemental Table 1:** Definitions of carbapenem-resistant Enterobacterales

621 (CRE) and difficult-to-treat resistance (DTR) used during the study period.

622

623

Definition	Period	Species	Susceptibility Phenotype
Initial GA EIP surveillance definition	2011–2015	<i>Escherichia coli</i> <i>Klebsiella pneumoniae</i> <i>Klebsiella oxytoca</i> <i>Enterobacter cloacae</i> complex <i>Klebsiella aerogenes</i> ^a	<u>Intermediate or resistant to:</u> - Imipenem (MIC ≥2 µg/mL), or - Meropenem (MIC ≥2 µg/mL), or - Doripenem (MIC ≥2 µg/mL) <u>AND resistant to^b:</u> - Ceftazidime (MIC ≥16 µg/mL), and - Ceftriaxone (MIC ≥4 µg/mL), and - Cefotaxime (MIC ≥4 µg/mL)
Revised GA EIP surveillance definition	2016–present	<i>Escherichia coli</i> <i>Klebsiella pneumoniae</i> <i>Klebsiella oxytoca</i> <i>Enterobacter cloacae</i> complex <i>Klebsiella aerogenes</i> ^a	<u>Resistant to:</u> - Imipenem (MIC ≥4 µg/mL), or - Meropenem (MIC ≥4 µg/mL), or - Doripenem (MIC ≥4 µg/mL), or - Ertapenem (MIC ≥2 µg/mL)

DTR	2011–2017	<i>Enterobacter cloacae</i> complex	Intermediate or resistant to all tested and reported agents in carbapenem, β -lactam, and fluoroquinolone categories

624

625 a. Formerly *Enterobacter aerogenes*

626 b. If the antibiotics were tested

627

628 Abbreviations: GA EIP: Georgia Emerging Infections Program; DTR: difficult-to-treat

629 resistance; MIC: minimum inhibitory concentrations

630

631

632

633 **Supplementary Table 2: Antimicrobial Susceptibility testing of Carbapenem-**
 634 **resistant *E. cloacae* complex by *mcr-9* status**

635

636

Antibiotic	Median (range) MIC*		Susceptible N (%)		Intermediate N (%)**		Resistant N (%)		P value
	<i>mcr-9</i> positive	<i>mcr-9</i> negative	<i>mcr-9</i>	<i>mcr-9</i>	<i>mcr-9</i>	<i>mcr-9</i>	<i>mcr-9</i>	<i>mcr-9</i>	***
	(n=13)	(n=14)	positive	negative	positive	negative	positive	negative	
			(n=13)	(n=14)	(n=13)	(n=14)	(n=13)	(n=14)	
Aminoglycosides									
Amikacin	≤1 (≤1->64)	≤1 (≤1-16)	12 (92.3)	14 (100)	0 (0)	0 (0)	1 (7.7)	0 (0)	0.97
Gentamicin	8 (≤0.25->16)	0.37 (≤0.25->16)	4 (30.8)	11 (78.6)	3 (23.1)	1 (7.1)	6 (46.2)	2 (14.3)	0.04
Tobramycin	8 (≤0.5->16)	≤0.5 (≤0.5 ->16)	3 (23.1)	9 (64.3)	4 (30.8)	2 (14.3)	6 (46.2)	3 (21.4)	0.10
B-lactams									
Aztreonam	>64 (64->64)	>64 (32->64)	0 (0)	0 (0)	0 (0)	0 (0)	13 (100)	14 (100)	n/a
Ceftriaxone	>32 (16->32)	>32 (32->32)	0 (0)	0 (0)	0 (0)	0 (0)	13 (100)	14 (100)	n/a
Ceftazidime	>128 (64->128)	>128 (64->128)	0 (0)	0 (0)	0 (0)	0 (0)	13 (100)	14 (100)	n/a
Cefepime	>32 (1->32)	16 (≤0.5 ->32)	1 (7.7)	5 (35.7)	1 (7.7)	1 (7.1)	11 (84.6)	8 (57.1)	0.21
Ertapenem	8 (≤0.12->8)	4 (0.25->8)	2 (15.4)	3 (21.4)	0 (0)	0 (0)	11 (84.6)	11 (78.6)	1.00
Doripenem	2 (≤0.12-8)	1 (≤0.12-8)	5 (38.5)	8 (57.1)	3 (23.1)	2 (14.3)	5 (38.5)	4 (28.6)	0.61
Imipenem	2 (≤0.5-8)	1 (≤0.5->64)	5 (38.5)	7 (50.0)	2 (15.4)	1 (7.1)	6 (46.2)	6 (42.9)	0.73
Piperacillin-Tazobactam	>128 (16->128)	>128 (≤4->128)	1 (7.7)	1 (7.1)	1 (7.7)	0 (0)	11 (84.6)	13 (92.9)	0.57
Meropenem	2 (≤0.12->8)	0.5 (≤0.12->8)	5 (38.5)	8 (57.1)	4 (30.8)	0 (0)	4 (30.8)	6 (42.9)	0.08
Fluoroquinolones									
Ciprofloxacin	>8 (0.5->8)	3 (≤0.25->8)	0 (0)	6 (42.9)	1 (7.7)	0 (0)	12 (92.3)	8 (57.1)	0.02
Levofloxacin	>8 (0.1->8)	3 (≤0.12->8)	0 (0)	6 (42.9)	1 (7.7)	0 (0)	12 (92.3)	8 (57.1)	0.02
Tetracyclines									
Tetracycline	16 (≤2.0->32)	4 (≤2-32)	5 (38.5)	9 (64.3)	1 (7.7)	1 (7.1)	7 (53.8)	4 (28.6)	0.38
Tigecycline	1 (≤0.5->4)	0.76 (≤0.5->4)	11 (84.6)	9 (64.3)	1 (7.7)	4 (28.6)	1 (7.7)	1 (7.1)	0.37
Miscellaneous									
Trimethoprim-	>8 (1->8)	(≤0.5 (≤0.5->8)	2 (15.4)	12 (85.7)	0 (0)	0 (0)	11 (84.6)	2 (14.3)	0.001

Sulfamethoxazole

637

638 * MICs in $\mu\text{g/mL}$

639 ** Intermediate is equivalent to the category susceptible dose dependent for cefepime

640 *** Calculated for proportion *mcr-9* positive categorized as S/I/R compared to *mcr-9*

641 negative isolates.

642

643 Abbreviation: MIC: minimum inhibitory concentration

644

645

646

647

648 **Supplementary Table 3: Plasmid contents of Carbapenem-resistant *E. cloacae***

649 **complex genomes *by mcr-9 status***

650

Isolate	Plasmid	Identity (%)	Plasmid Accession
<i>mcr-9</i> positive			
SRR10377147	ColRNAI	100	DQ298019
	IncFIA(HI1)	98.0	AF250878
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
SRR3467253	IncHI2A	100	BX664015
SRR4035127	IncHI2A	99.5	BX664015
	IncFII(pECLA)	96.8	CP001919
	IncFIB(pECLA)	99.5	CP001919
SRR4035132	IncHI2A	100	BX664015
	IncR	100	DQ449578
SRR5666570	Col440I	83.2	CP023920
	IncFII(pECLA)	96.1	CP001919
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
SRR5666425	IncHI2A		BX664015
SRR5666426	IncFIA(HI1)	98.0	AF250878
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
SRR5666432	IncFIB(pB171)	91.2	AB024946

	IncFII(SARC14)	94.8	JQ418540
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
SRR10377089	Col440I	83.2	CP023920
	Col440II	84.6	CP023921
	IncHI2A	100	BX664015
	IncX5	99.7	MF062700
SRR10377142	IncFIA(HI1)	98.0	AF250878
	IncFIB(pECLA)	100	CP001919
	IncFII(pECLA)	100	CP001919
	IncHI2A	100	BX664015
	Col440II	83.9	CP023921
SRR10377154	IncFIB(pECLA)	100	CP001919
	IncFII(pECLA)	100	CP001919
	IncFIA(HI1)	98.0	AF250878
SRR12902635	IncFIB(pECLA)	100	CP001919
	IncFII(pECLA)	100	CP001919
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
	IncFIA(HI1)	97.8	AF250878
SRR12902473	IncFIB(pECLA)	100	CP001919
	IncFII(pECLA)	100	CP001919
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
	Col440II	84.3	CP023921
SRR6674815	IncFIB(pECLA)	100	CP001919

	IncFII(pECLA)	99.6	CP001919
	IncHI2A	100	BX664015
	IncN	99.6	AY046276
	IncR	100	DQ449578
	Col(pHAD28)		
	Col440II	90.8	CP023921
	IncFIB(K)	84.8	JN233704
SRR6674819	IncFII(pECLA)	99.5	CP001919
	IncHI2A	100	BX664015
	IncQ2	94.2	FJ696404
	IncR	100	DQ449578
SRR6674864	IncHI2A	100	BX664015
	pKPC-CAV1193	100	CP013325
<i>mcr-9</i> negative			
SRR3996257	Col440II	84.4	CP023921
	IncX3	100	JN247852
SRR4035128	n/a		
SRR4035129	Col440II	84.6	
	pKPC-CAV1193	100	CP013325
SRR4035130	n/a		
SRR4035131	n/a		
SRR12902528	Col440II	84.4	CP023921
	IncFII(pECLA)	99.9	CP001919
	IncFIB(pECLA)	100	CP001919
	IncFIB(pENTE01)	81.1	CP000654
SRR5666492	IncFII(pECLA)	100	CP001919
	IncHI1A(NDM-CIT)	100	JX182975

	IncHI1B(pNDM-CIT)	99.1	JX182975
	Col440II	84.4	CP023921
	IncFIB(pB171)	91.2	AB024946
SRR10377150	IncFIB(pHCM2)	97.5	AL513384
	IncFII(SARC14)	94.8	JQ418540
	pKPC-CAV1193	98.7	CP013325
	IncX5	100	
SRR10377039	pKPC-CAV1193	100	CP013325
	IncFIA(HI1)	97.8	AF250878
	IncFIB(pECLA)	100	CP001919
SRR10377142	IncFII(pECLA)	100	CP001919
	IncHI2A	100	BX664015
	IncFII(pECLA)	97.5	
SRR10377155	IncR	94.0	
	IncFIB(pECLA)	100	CP001919
SRR12902580	IncFII(pECLA)	100	CP001919
	IncFIB(pECLA)	100	CP001919
SRR12902479	IncFII(pECLA)	100	CP001919
	IncFIB(pHCM2)	97.3	AL513384
SRR12902477	IncFIB(pQil)	100	JN233705
SRR3996257	IncX3	100	JN247852
SRR6674810	IncN	99.8	AY046276
	IncFIB(pECLA)	100	CP001919
	IncFIB(pENTE01)	80.7	CP000654
SRR6674817	IncFIB(pQil)	100	JN233705
	IncFII(pECLA)	97.9	CP001919
	IncQ2	81.1	FJ696404

	pKPC-CAV1193	100	CP013325
	IncFIB(pECLA)	100	CP001919
	IncFIB(pENTE01)	80.7	CP000654
SRR6674821	IncFIB(pQil)	100	JN233705
	IncFII(pECLA)	99.9	CP001919
	IncQ2	81.1	FJ696404
	pKPC-CAV1193	100	CP013325
SRR6674823	IncFIB(pENTAS01)	93.2	CP003027
	IncFII(SARC14)	99.5	JQ418540
	Col440II	84.0	CP023921
SRR6674824	IncFIB(pECLA)	100	CP001919
	IncFII(pECLA)	99.6	CP001919
	IncN	99.8	AY046276
	IncR	100	DQ449578
SRR6674865	IncN	99.8	AY046276

651

652

Supplementary Figures

Supplementary Figure 1

Supplementary Figure 1 legend: Waffle-plot of Carbapenem-resistant

Enterobacterales cases by species collected by Georgia Emerging Infections Program

between 2012-2017.

Supplementary Figure 2

Supplementary Figure 2 legend: Phylogeny of *mcr-9* positive (n=13) and *mcr-9* negative (n=14) *E. cloacae* complex from Georgia Emerging Infections program (GA EIP) in addition to 9 available *E. cloacae* complex (three *mcr-9* positive, six *mcr-9* negative) from the National Institutes of Health. A phylogenetic tree based on a core gene alignment containing 1,904 genes defined using Roary v3.13.0. was generated using IQtree v2.0.3. A maximum likelihood tree was generated by running 1,000 bootstrap replicates under the generalized time-reversible model of evolution. The tree

680 was visualized and Facility IDs and year of isolation were annotated using Interactive
681 Tree of Life (iTOL) v4. for GA EIP *mcr-9* positive genomes only.

682

683 Abbreviations: GA EIP: Georgia Emerging Infections Program, NIH: National Institutes
684 of Health

685

Supplementary Figure 3

Supplementary Figure 3 Legend: Genomes were annotated using Prodigal and virulence gene content was assessed using AMRFinder. Virulence gene

693 presence/absence heatmaps were created using the package pheatmap on R version
694 4.0.2 (Vienna, Austria) and the RStudio interface version 1.3.1073 (Boston, MA, USA).
695